文献速递中医内科中药与中成药合理使用

丹参-山楂方治疗动脉粥样硬化:民族药理、制备、成分、药动学与药理作用综述

Danshen-Shanzha formula for the treatment of atherosclerosis: ethnopharmacological relevance, preparation methods, chemical constituents, pharmacokinetic properties, and pharmacological effects.
PubMed 文献 · Front Pharmacol · 2024-06-07

本文综述丹参-山楂方(DSF)的民族药理相关性、制备方法、化学成分、药代动力学特性及药理作用。DSF由丹参和山楂组成,长期用于治疗动脉粥样硬化性心脑血管疾病。作者基于多个数据库和典籍资料汇总信息,并提出未来研究应统一标准制备方法、阐明配伍机制及开展更广泛的临床研究。

要点

  • DSF由丹参和山楂组成,具有活血化瘀功效,广泛用于动脉粥样硬化性心脑血管疾病。
  • 综述涵盖民族药理、制备方法、化学成分、药代动力学及药理作用。
  • 未来需统一标准制备、阐明配伍机制并开展更广泛临床研究。

核心结论

  • DSF在基础研究和临床应用方面已取得若干突破,但缺乏全面综述总结其特征和研究,阻碍了进一步开发。
  • 本综述为DSF的深入研究提供数据支持和更广阔的视角。

研究设计与样本

  • 综述性研究,检索Web of Science、PubMed、Google Scholar、中国知网、百度学术、ScienceDirect、ACS Publications、Online Library、万方数据库及Flora of China等数据库。
  • 资料还来自文献、印刷作品和典籍,如《中国药典》、《中药大辞典》等。

主要发现

  • DSF由丹参(Radix Salvia Miltiorrhiza)和山楂(Fructus Crataegi)组成,具有活血化瘀作用。
  • DSF数十年来广泛用于治疗动脉粥样硬化性心脑血管疾病。

关键数值与推荐

  • 未来研究应开发并统一DSF的标准制备方法,以实现优化的药理特性。
  • 应阐明DSF的功能机制及配伍合理性,聚焦临床证候并建立体外和体内临床前研究体系。
  • 应开展更广泛的临床研究,以循证医学推进DSF安全应用的机制研究。

临床怎么用

  • 临床可用于动脉粥样硬化性心脑血管疾病的活血化瘀治疗,但需注意目前证据来自综述汇总,具体应用应结合临床实际。

局限性

  • 原文未报告具体研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Danshen-Shanzha Formula (DSF) is a well-known herbal combination comprising Radix Salvia Miltiorrhiza (known as Danshen in Chinese) and Fructus Crataegi (known as Shanzha in Chinese), It has been documented to exhibit considerable benefits for promoting blood circulation and removing blood stasis, and was used extensively in the treatment of atherosclerotic cardiac and cerebral vascular diseases over decades. Despite several breakthroughs achieved in the basic research and clinical applications of DSF over the past decades, there is a lack of comprehensive reviews summarizing its features and research, which hinders further exploration and exploitation of this promising formula. This review aims to provide a comprehensive interpretation of DSF in terms of its ethnopharmacological relevance, preparation methods, chemical constituents, pharmacokinetic properties and pharmacological effects. The related information on Danshen, Shanzha, and DSF was obtained from internationally recognized online scientific databases, including Web of Science, PubMed, Google Scholar, China National Knowledge Infrastructure, Baidu Scholar, ScienceDirect, ACS Publications, Online Library, Wan Fang Database as well as Flora of China. Data were also gathered from documentations, printed works and classics, such as the Chinese Pharmacopoeia, Chinese herbal classics, etc. Three essential avenues for future studies were put forward as follows: a) Develop and unify the standard preparation method of DSF as to achieve optimized pharmacological properties. b) Elucidate the functional mechanisms as well as the rationality and rule for the compatibility art of DSF by focusing on the clinic syndromes together with the subsequent development of preclinic study system in vitro and in vivo with consistent pathological features, pharmacokinetical behaviour and biomarkers. c) Perform more extensive clinical studies towards the advancement of mechanism-based on evidence-based medicine on the safety application of DSF. This review will provide substantial data support and broader perspective for further research on the renowned formula.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Xu Q, Yu Z, Zhang M, et al. Danshen-Shanzha formula for the treatment of atherosclerosis: ethnopharmacological relevance, preparation methods, chemical constituents, pharmacokinetic properties, and pharmacological effects. Front Pharmacol. 2024. PMID: 38910885. doi:10.3389/fphar.2024.1380977

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。